1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Malignant Fibrous Histiocytoma Of Bone Global Clinical Trials Review, H1, 2014

Malignant Fibrous Histiocytoma Of Bone Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Malignant Fibrous Histiocytoma Of Bone Global Clinical Trials Review, H1, 2014" provides data on the Malignant Fibrous Histiocytoma Of Bone clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Fibrous Histiocytoma Of Bone. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Fibrous Histiocytoma Of Bone. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Malignant Fibrous Histiocytoma Of Bone Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Malignant Fibrous Histiocytoma Of Bone 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Malignant Fibrous Histiocytoma Of Bone to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Unaccomplished Trials of Malignant Fibrous Histiocytoma Of Bone 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Drugs 22
Clinical Trial Overview of Top Institutes / Government 23
National Cancer Institute 23
Clinical Trial Overview of National Cancer Institute 23
Children's Oncology Group 24
Clinical Trial Overview of Children's Oncology Group 24
St. Jude Children's Research Hospital 25
Clinical Trial Overview of St. Jude Children's Research Hospital 25
European Paediatric Soft Tissue Sarcoma Study Group 26
Clinical Trial Overview of European Paediatric Soft Tissue Sarcoma Study Group 26
University of Miami Sylvester Comprehensive Cancer Center 27
Clinical Trial Overview of University of Miami Sylvester Comprehensive Cancer Center 27
Memorial Sloan Kettering Cancer Center 28
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 28
Societe Internationale d'Oncologie Pediatrique 29
Clinical Trial Overview of Societe Internationale d'Oncologie Pediatrique 29
National Center for Research Resources 30
Clinical Trial Overview of National Center for Research Resources 30
The University of Texas M. D. Anderson Cancer Center 31
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 31
Five Key Clinical Profiles 32
Appendix 128
Abbreviations 128
Definitions 128
Research Methodology 129
Secondary Research 129
About GlobalData 130
Contact Us 130
Disclaimer 130
Source 131

List of Tables
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Region, 2014* 6
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Malignant Fibrous Histiocytoma Of Bone to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Malignant Fibrous Histiocytoma Of Bone Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Malignant Fibrous Histiocytoma Of Bone Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Withdrawn Clinical Trials, 2014* 19
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Malignant Fibrous Histiocytoma Of Bone Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 21
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 22
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 23
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 24
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Jude Children's Research Hospital, 2014* 25
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by European Paediatric Soft Tissue Sarcoma Study Group, 2014* 26
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami Sylvester Comprehensive Cancer Center, 2014* 27
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 28
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by Societe Internationale d'Oncologie Pediatrique, 2014* 29
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 30
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 31

List of Figures
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Malignant Fibrous Histiocytoma Of Bone to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Malignant Fibrous Histiocytoma Of Bone Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Malignant Fibrous Histiocytoma Of Bone Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Malignant Fibrous Histiocytoma Of Bone Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Malignant Fibrous Histiocytoma Of Bone Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 21
Malignant Fibrous Histiocytoma Of Bone Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 22
GlobalData Methodology 129

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.